Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant versus postoperative adjuvant tislelizumab + lenvatinib for high-risk recurrent hepatocellular carcinoma
ChiCTR2400094607Phase 2Recruiting
- Sponsor
- The First Medical Center of Chinese PLA General Hospital
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by The First Medical Center of Chinese PLA General Hospital. Primary endpoint: Recurrence-free survival. Started Dec 2024; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400094607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094607.